BRILINTA — Class I drug recall D-0958-2017
Terminated recall by AstraZeneca Pharmaceuticals, LP, reported 2017-07-19, distributed nationwide. Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as
| Recall number | D-0958-2017 |
|---|---|
| Product type | Drug |
| Classification | Class I |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | AstraZeneca Pharmaceuticals, LP, Newark, DE, United States |
| Recall initiated | 2017-05-25 |
| Classified | 2017-07-11 |
| Reported by FDA | 2017-07-19 |
| Terminated | 2018-04-24 |
| Distributed | Nationwide (US) |
| Quantity | 40,368 bottles |
| Reason classes | labeling |
| NDC | 00186-0776, 00186-0776-60, 00186-0776-94, 00186-0777, 00186-0777-08, 00186-0777-18, 00186-0777-28, 00186-0777-39, 00186-0777-60 |
| Lot numbers | 10/19, JB5047 |
Product
BRILINTA (ticagrelor) tablets, 90 mg, 8-count Professional Sample bottles, Rx only, Mfd. for: AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850; By: AstraZeneca AB, SE-151 85 Sodertalje, Sweden, NDC 0186-0777-08.
Reason for recall
Presence of Foriegn Tablets/Capsules: customer complaint that an 8-count professional sample bottle labeled as BRILINTA 90 mg tablets contained 5 ZURAMPIC 200 mg tablets, in addition to the expected 8 BRILINTA tablets.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0958-2017. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.